Lyramid: Cancer Treatment and Detection
holds the largest and most comprehensive global portfolio of intellectual
property (IP) related to the novel oncology target midkine (MK). MK is
highly expressed in over 26 cancers and enhances a variety of significant tumorigenic
effects such as: survival, angiogenesis, migration and chemo-resistance. Cellmid is using its
strong IP position around MK to develop innovative novel targeted therapies and
diagnostic tests for a number of cancer indications.
expression in cancer (Jones, 2014, British Journal of Pharmacology)
Cellmid is developing a first-in-class
anti-MK antibody as a lead drug candidate in oncology. The anti-MK
antibody is designed to inhibit MK’s tumorigenic effects, making it an ideal
and potent candidate for the treatment of numerous cancers. In addition to direct
action on malignant cells to modulate migration and survival, MK inhibits angiogenesis,
modulates inflammatory cell recruitment and reduces resistance of tumors to
Cellmid’s anti-MK antibody has strong
potential for a firm positioning within the anti-cancer treatment market, which
is currently worth over US$ 100 billion and is growing rapidly in all markets.
Cancers are complex diseases with
heterogeneity at individual patient level. The premise of personalised
medicine is that patients can be treated with drugs that are most likely to be
effective. Cellmid has developed and validated a companion diagnostic for
the company’s anti-MK antibody therapy (MK ELISA).
The MK ELISA will be used to
stratify patients and help group patients that would most benefit from anti-MK
targeted therapy, as well as monitoring for response and relapse after
treatment, making it a direct marker of drug efficacy. This
provides Cellmid with a significant advantage in the regulatory and clinical environment,
where there is increasing demand to target treatments to patients who are
likely to respond, and correspondingly for those patients to be closely
monitored for response and relapse.
Midkine has high expression in over 20
cancer types and low expression in healthy adults making it a useful and
sensitive cancer maker. Early detection is often a key factor in reducing
mortality rates and Cellmid’s midkine detection technology promises to deliver
a highly sensitive and cost-effective method for early detection and monitoring
of many cancer types.
In addition to Cellmid’s validated
companion diagnostic, Cellmid’s midkine detection technology can be adapted to
various platforms used in the diagnosis of cancer, including multiplexing
midkine with other biomarkers. Multiplexing not only increases sensitivity and specificity but
is useful in precise targeting of cancer types.
Using multiplexed tests can substantially reduce rates of false
detection and optimise treatment pathways, presenting physicians with safer and
more effective options for diagnosis and treatment.
Cellmid’s midkine biomarker for the detection of cancer has strong
potential for a firm positioning within the in
vitro diagnostics (IVD) market worth an estimated US$ 59 billion, of which
immunoassays, such as the midkine detection technology, comprise a market share
of US$ ~18 billion. Oncology biomarkers comprise the fastest growing market
within IVD and companion diagnostics as well as molecular diagnostics show
great promise for increased growth within this area.
is currently out-licensing its MK technology for inclusion in two novel cancer
diagnostic multiplex tests for which Cellmid is expected to receive royalties
on sales. The first licensed product, CxBladder®, is already on market and
generating revenue of which Cellmid recieves single digit royalties.
was developed by Cellmid Licensee Pacific Edge Biotechnology. The urine-based
detection and monitoring test that measures gene expression of MK and four
other markers is used for the diagnosis of bladder cancer in patients
presenting with blood in their urine.
is an effective alternative to cystoscopy, which is a painful and invasive
procedure used in monitoring for recurrence of bladder cancer and it is
expected to make a meaningful difference in a patient’s treatment. This novel test
has seen successfully launched in the United States of America, Spain, New Zealand and
Australia with distribution in other countries on the horizon. Cellmid's Licensee Pacific Edge Biotechnology has reported a 162% increase in operating revenue FY2015 - FY2016 and an exponential growth in revenue from NZ$ 150 000 to NZ$ 4.98 million in just two years.
a first-in-class drug, a validated companion diagnostic, and successful
licensing of the MK technology, Cellmid is in an outstanding position to access
the rapidly growing oncology market.